Edwards Lifesciences Corp
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
EW$104.71+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in millions, except per share information)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net sales | $5,439.5 | $5,010.0 | $4,464.0 |
| Cost of sales | 1,117.5 | 978.4 | 723.7 |
| Gross profit | 4,322.0 | 4,031.6 | 3,740.3 |
| Selling, general, and administrative expenses | 1,789.2 | 1,582.5 | 1,357.6 |
| Research and development expenses | 1,053.0 | 962.9 | 843.6 |
| Intellectual property agreement and certain litigation expenses (Note 3) | 40.4 | 203.5 | 15.8 |
| Change in fair value of contingent consideration liabilities (Note 13) | — | (26.2) | (35.8) |
| Restructuring charges, separation costs, and other (Note 4) | 61.0 | — | 60.7 |
| Other operating income, net | (0.3) | — | — |
| Operating income | 1,378.7 | 1,308.9 | 1,498.4 |
| Interest expense | 19.8 | 17.6 | 19.2 |
| Interest income | (120.3) | (67.2) | (35.5) |
| Other non-operating income, net (Note 18) | (68.9) | (13.9) | (4.8) |
| Income from continuing operations before provision for income taxes | 1,548.1 | 1,372.4 | 1,519.5 |
| Provision for income taxes (Note 19) | 152.1 | 152.4 | 195.5 |
| Net income from continuing operations | 1,396.0 | 1,220.0 | 1,324.0 |
| Income from discontinued operations, net of tax | 2,773.7 | 179.4 | 197.9 |
| Net income | 4,169.7 | 1,399.4 | 1,521.9 |
| Net loss attributable to noncontrolling interest | (4.9) | (3.0) | — |
| Net income attributable to Edwards Lifesciences Corporation. | $4,174.6 | $1,402.4 | $1,521.9 |
| Share information (Note 2): | |||
| Earnings per share attributable to Edwards Lifesciences Corporation: | |||
| Basic | |||
| Continuing operations | $2.34 | $2.02 | $2.14 |
| Discontinued operations | $4.64 | $0.29 | $0.32 |
| Basic earnings per share | $6.98 | $2.31 | $2.46 |
| Diluted | |||
| Continuing operations | $2.34 | $2.01 | $2.12 |
| Discontinued operations | $4.63 | $0.29 | $0.32 |
| Diluted earnings per share | $6.97 | $2.30 | $2.44 |
| Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation: | |||
| Basic | 597.7 | 606.7 | 619.0 |
| Diluted | 599.3 | 609.4 | 624.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.